Drug information of Hib vaccine

Hib vaccine

Drug group:

The vaccine contains the Haemophilus influenzae type b capsular polysaccharide (polyribosyl-ribitol-phosphate, PRP), a high-molecular-weight polymer prepared from the H. influenzae type b strain 1482 grown in a semi-synthetic medium.

Mechanism of effect

Antigenic capsular polysaccharides induce Ab production.


The onset of protection from disease is relatively slow, but duration is long lasting (years)



H. influenzae Type B Immunization


  • One dose of HIB vaccine should be administered if HIB vaccine not previously received
  • HIB vaccination should be given ≥14 days before splenectomy

Complement deficiency

  • One dose of HIB vaccine should be administered if HIB vaccine not previously received

Post-HSCT Recipients

  • Recipients of a hematopoietic stem cell transplant (HSCT) should be vaccinated with a 3-dose regimen 6 to 12 months after a successful transplant, regardless of vaccination history
  • At least 4 weeks should separate doses


H. influenzae Type B Immunization

IM injection indicated for routine immunization in children aged 2 months to 15 months and up to 5 years for catch up vaccination

Primary series (6 weeks to 12 months): 2 or 3 doses

Booster: 3rd or 4th dose between 12-15 months

Side effects

vertigo , fever , anorexia , swelling , Restlessness


If Guillain-Barré syndrome has occurred within 6 wk of receipt of a prior vaccine containing tetanus toxoid, the decision to give any tetanus toxoid-containing vaccine should be based on careful consideration of the potential benefits and possible risks

Syncope can occur in association with administration of injectables and may be accompanied by transient neurological signs (eg, visual disturbance, paresthesia, tonic-clonic limb movements): procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope

Apnea reported following IM vaccination in some infants born prematurely; decisions about when to administer an IM vaccine to infants born prematurely should be based on consideration of the individual infant’s medical status, and the potential benefits and possible risks of vaccination

Prior to administration, the healthcare provider should review the patient's immunization history for possible vaccine hypersensitivity; epinephrine and other appropriate agents used for the control of immediate allergic reactions must be immediately available should an acute anaphylactic reaction occur

Safety and effectiveness in immunosuppressed children have not been evaluated; if administered to immunosuppressed children, the expected immune response may not be obtained

Points of recommendation

Your doctor may recommend reducing fever and pain by giving the child an aspirin-free pain reliever such as acetaminophen or ibuprofen when the shot is given and for the next 24 hours.

Related drugs


Ask a Pharmacist

User's questions
    No comments yet.